



7th November 2016

BSE Limited
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400001

National Stock Exchange of India Limited
Exchange Plaza, 5th Floor,
Plot No.C/1, G Block,
Bandra Kurla Complex
Bandra (East), Mumbai 400051

Scrip Code: 500674

Scrip Code: SANOFI

Dear Sirs,

Re: Unaudited Financial Results for quarter ended 30th September 2016

We enclose herewith the Unaudited Financial Results of the Company for the quarter ended 30th September 2016 which were approved by the Board of Directors at its meeting held today.

The Board meeting commenced at 3:30 p.m. and concluded at 5:35 p.m.

A handwritten signature in blue ink, appearing to be "K. Subramani", is written to the right of the meeting time information.

As required by Regulation 33 (3) (c) (i) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we also enclose herewith the Limited Review Report.

Thanking you,

Yours faithfully,

SANOFI INDIA LIMITED

A handwritten signature in blue ink, appearing to be "K. Subramani", is written below the company name.

K.SUBRAMANI
COMPANY SECRETARY

Encl: a/a

Limited Review Report

**Review Report to
The Board of Directors
Sanofi India Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Sanofi India Limited ('the Company') for the quarter and nine months ended September 30, 2016 (the "Statement"). This Statement is the responsibility of the Company's management and has been approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.
2. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
3. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For S R B C & CO LLP

ICAI Firm registration number: 324982E/E300003

Chartered Accountants


per Vijay Maniar

Partner

Membership No.: 36738



Place: Mumbai

Date: November 07, 2016

SANOFI INDIA LIMITED

Registered Office : Sanofi House, C.T.S No - 117-B, L & T Business Park, Saki Vihar Road, Powai, Mumbai 400 072.

Corporate Identity Number: L24239MH1956PLC009794

Tel no: (91-22) 28032000 Fax No: (91-22) 28032846


Website: www.sanofiindia.com Email: igrcsil@sanofi.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2016

PART I Particulars	Rs. Million					
	Quarter ended 30.09.2016 Unaudited	Quarter ended 30.06.2016 Unaudited	Quarter ended 30.09.2015 Unaudited	Nine Months ended 30.09.2016 Unaudited	Nine Months ended 30.09.2015 Unaudited	Year ended 31.12.2015 (Audited)
1. Income from Operations						
(a) Net Sales (net of excise duty)	5,828	5,653	5,528	16,544	15,269	20,493
(b) Other Operating Income	414	427	330	1,222	975	1,438
Total income from Operations (net)	6,242	6,080	5,858	17,766	16,244	21,931
2 Expenditure						
(a) Cost of Materials Consumed	1,539	1,491	1,620	4,684	4,325	6,339
(b) Purchase of stock in trade	1,816	843	564	3,898	3,112	3,413
(c) Changes in inventories of finished goods, work in progress and stock in trade	(430)	467	468	(429)	146	364
(d) Employee benefits expense	948	846	812	2,630	2,388	3,333
(e) Depreciation and amortisation expense	300	300	290	901	834	1,130
(f) Other expenses	922	963	975	2,775	2,811	3,891
(g) Total Expenses	5,095	4,910	4,729	14,459	13,616	18,470
3 Profit from Operations before other income, finance costs and exceptional items (1-2)	1,147	1,170	1,129	3,307	2,628	3,461
4 Other Income	148	152	94	556	388	514
5 Profit before finance costs and exceptional items (3+4)	1,295	1,322	1,223	3,863	3,016	3,975
6 Finance costs	3	7	1	11	3	4
7 Profit before tax and exceptional items (5-6)	1,292	1,315	1,222	3,852	3,013	3,971
8 Tax expense	486	462	497	1,387	1,161	1,594
9 Net Profit for the period before exceptional items (7-8)	806	853	725	2,465	1,852	2,377
10 Exceptional item (net of tax)	-	-	-	-	161	838
11 Net Profit for the period after exceptional items (9+10)	806	853	725	2,465	2,013	3,215
12 Paid-up equity share capital (Face Value of Rs 10 per share)	230	230	230	230	230	230
13 Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	-	-	16,004
14 Earnings Per Share (EPS) before Exceptional items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	35.04	37.09	31.52	107.17	80.51	103.18
15 Earnings Per Share (EPS) after Exceptional items (Rs.) (Basic and diluted EPS for the period, for the year to date and for the previous year)	35.04	37.09	31.52	107.17	87.50	139.59

Q


2

SIGNED FOR IDENTIFICATION
BY

S R B & CO LLP
MUMBAI

LG

Notes:

1. The above Results were approved by the Board of Directors of the Company at its Meeting held on November 7, 2016.
2. In accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company's Statutory Auditors have conducted a 'Limited Review' of the Financial Results for the quarter ended September 30, 2016.
3. The Board of Directors had declared an Interim Dividend of Rs.18 per Equity share of Rs 10 for the year ending December 31, 2016. The said Dividend was paid on August 16, 2016.
4. The Company has a single business segment namely 'Pharmaceutical Business'.
5. The figures for the previous periods have been re-grouped, wherever necessary.



November 7, 2016

SANOFI INDIA LIMITED

SHAILESH AYYANGAR

MANAGING DIRECTOR